Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2026)

Pacira BioSciences' Long-Term Deferred Tax history runs 7 years deep, the most recent figure standing at $122.1 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 5.34% year-over-year to $122.1 million in Q1 2026; TTM through Mar 2026 was $122.1 million, a 5.34% decrease from a year earlier, with the FY2025 full-year figure at $123.9 million, down 5.0% from the prior year.
• Long-Term Deferred Tax fell to $122.1 million in Q1 2026 per PCRX's latest filing, from $123.9 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $169.3 million in Q1 2022 and bottomed at $120.2 million in Q3 2025.
• The 5-year median for Long-Term Deferred Tax is $141.1 million (2024), against an average of $143.3 million.
• Across the five-year window, Long-Term Deferred Tax soared 69.52% in 2022 and slipped 15.82% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $160.3 million in 2022, then dropped by 9.87% to $144.5 million in 2023, then decreased by 9.77% to $130.4 million in 2024, then declined by 5.0% to $123.9 million in 2025, then slipped by 1.4% to $122.1 million in 2026.
• Per Business Quant, the three latest PCRX Long-Term Deferred Tax figures stand at $122.1 million (Q1 2026), $123.9 million (Q4 2025), and $120.2 million (Q3 2025).